Uganda

The National Drug Authority (NDA) of Uganda is the primary regulatory body responsible for overseeing the safety, quality, and efficacy of health products, including pharmaceuticals, medical devices, diagnostics, and herbal medicines. Established under the National Drug Policy and Authority Act (Cap 206), the NDA operates under the Ministry of Health and administers product registration, post-market surveillance, import and export licensing, and facility inspection. All health products intended for the Ugandan market must be registered with the NDA before they can be legally imported, manufactured, or distributed. The registration process involves a structured technical review conducted by NDA evaluators, with product classifications determining the depth of review required. Uganda is also a member state of the East African Community (EAC) and participates in regional harmonization efforts under the EAC Medicines Regulatory Harmonization (MRH) program, which allows for joint reviews that can streamline approval for products simultaneously seeking registration across member states.

Applicants are required to appoint a local registered agent or representative based in Uganda to liaise with the NDA throughout the registration and post-registration lifecycle. Dossiers are generally accepted in the Common Technical Document (CTD) format, and the NDA recognizes reference agency approvals from stringent regulatory authorities (SRAs) such as the US FDA, EMA, Health Canada, and the UK MHRA, which can facilitate an abridged or verified review pathway and potentially reduce timelines. Supporting documentation typically includes product quality data, clinical evidence, labeling compliant with Ugandan and regional standards, a Certificate of Pharmaceutical Product (CPP) from the country of origin, and Good Manufacturing Practice (GMP) certification for the manufacturing site. Recent reforms have focused on digitizing the submission and tracking process through the NDA online portal, improving transparency and reducing administrative delays. The NDA has also been strengthening its capacity for medical device and in vitro diagnostic regulation, aligning progressively with the African Union's African Medicines Regulatory Harmonisation (AMRH) initiative.

Public sector health product procurement in Uganda is primarily coordinated through the National Medical Stores (NMS), a government agency under the Ministry of Health responsible for the warehousing and distribution of medicines, medical supplies, and equipment to public health facilities. The NMS operates through a national quantification and procurement planning process, guided by the Ministry of Health's annual health sector work plans and the Uganda National Medicines Policy. Procurement decisions follow the Public Procurement and Disposal of Public Assets Act (PPDA), overseen by the Public Procurement and Disposal of Public Assets Authority (PPDA Authority), which sets standards for competitive tendering, framework contracts, and direct procurement under defined conditions. Large-volume tenders are typically conducted through open international competitive bidding, with evaluation criteria encompassing price, quality certification, and supplier reliability. The Joint Medical Stores (JMS), a faith-based organization with a mandate complementary to NMS, also procures and distributes health commodities to non-governmental and private not-for-profit health facilities, adding a significant parallel channel within the semi-public procurement landscape.

Donor-funded procurement represents a substantial portion of Uganda's health commodity supply, with major international partners including the Global Fund to Fight AIDS, Tuberculosis and Malaria, the US Government through USAID and PEPFAR, Gavi the Vaccine Alliance, UNICEF, and the World Bank all active in financing and sometimes directly procuring health products for Uganda's programs. These channels often operate through international procurement agents such as the UNICEF Supply Division, the USAID Global Health Supply Chain program, and the Clinton Health Access Initiative (CHAI), and products procured through these mechanisms may be subject to the procurement rules of the respective financing entity rather than solely Ugandan government processes. The private commercial sector, served through a network of licensed pharmaceutical wholesalers and distributors, provides a complementary channel particularly for diagnostics and medical devices. Uganda does not currently enforce a formal local manufacturing preference policy in public procurement, though the Government of Uganda has expressed strategic interest in promoting local pharmaceutical production as part of broader import substitution and health security objectives, in alignment with the African Union's Pharmaceutical Manufacturing Plan for Africa and regional EAC industrial development frameworks.